Current Standards for Treating Metastatic Urothelial Cancer
Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.
Risa Wong, MD, hematology/oncology fellow at the University of Washington, reviews the standard treatment options for patients with metastatic urothelial cancer (mUC).
Patients with mUC who are defined as fit, are treated with first-line platinum-based combination chemotherapy as standard of care, explain Wong. In the past, after patients subsequently progressed, there were very limited options for subsequent therapy, and providers ended up retreating many of these patients with chemotherapy, either rechallenging them with a platinum-based regimen or switching to a nonplatinum-based chemotherapy regimen.
In recent years, there have been many advances in the treatment landscape and these patients can now receive immune checkpoint inhibitors.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More
